65,437 trials
Congenital Protein C Deficiency
Primary: PK Part: Protein C Activity Level of TAK-662 — 0.000; 1.746; 1.616; 1.458 international unit per milliliter(IU/ml)
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Primary: Mean Change From Baseline in BCVA at Week 8 — 6.4; 6.5 Letters
Healthy Study Participants
Primary: Maximum Plasma Concentration (Cmax) for a Single Dose of Brivaracetam — 2.286; 1.989 micrograms per milliliter (μg/mL)
Anesthesia
Primary: Time to PACU Discharge — 123; 125 minutes
Smoking Cessation
Primary: Average Total App Openings at 12 Weeks — 86.5; 157.9 app openings
Type 1 Diabetes
Primary: Energy Expenditure — 1978.3; 1969.8; 2414.8; 1497.7 Kilocalories — p=0.24
Colorectal Cancer
Primary: Efficacy Based on Progression Free Survival of Vorinostat and Hydroxychloroquine Compared to Regorafenib — 1.9; 4.35 months
Chronic Kidney Disease · Cardiac Disease
Primary: Glomerular Filtration Rate at Baseline — 56; 67 mL/mnt/1.73 m^2
Diabetic Macular Edema
Primary: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52 for the Study Eye — 10.6; 9.4 Scores on a scale — p=<0.001
Vaccination Uptake
Primary: Percentage of Women With Reduced Number of Concerns Immediately Post-counseling in the Intervention Arm — 51.72 percentage of women
Heart Failure
Primary: Myocardial Energetic Efficiency — 48621.3; 50035.7; 50301.0; 52942.8 (((mmhg x ml x bpm) /g)/(1/min))
Recurrent Non-Small Cell Lung Carcinoma · Stage IIIB Non-Small Cell Lung Cancer · Stage IV Non-Small Cell Lung Cancer
Primary: Duration of Response — 98; 69 days — p=0.366
Multiple Sclerosis
Primary: Participant Muscle Stiffness Measure — 350.83; 240.07 Newton-metres
Radiation Dermatitis
Primary: Number of Participants With an Adverse Skin Event — 1 Participants
Healthy Adult Subjects
Primary: Area Under the Concentration Versus Time Curve From Zero up to Infinity (AUC0-inf) of Edaravone — 2165; 2209; 2073; 1955 ng·h/mL